Your browser doesn't support javascript.
loading
New opportunities to overcome T cell dysfunction: the role of transcription factors and how to target them.
Wu, Bocheng; Koehler, Angela N; Westcott, Peter M K.
Afiliação
  • Wu B; Koch Institute for Integrative Cancer Research, Cambridge, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: bocheng@mit.edu.
  • Koehler AN; Koch Institute for Integrative Cancer Research, Cambridge, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. Electronic address: koehler@mit.edu.
  • Westcott PMK; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA. Electronic address: westcott@cshl.edu.
Trends Biochem Sci ; 2024 Sep 13.
Article em En | MEDLINE | ID: mdl-39277450
ABSTRACT
Immune checkpoint blockade (ICB) therapies, which block inhibitory receptors on T cells, can be efficacious in reinvigorating dysfunctional T cell responses. However, most cancers do not respond to these therapies and even in those that respond, tumors can acquire resistance. New strategies are needed to rescue and recruit T cell responses across patient populations and disease states. In this review, we define mechanisms of T cell dysfunction, focusing on key transcription factor (TF) networks. We discuss the complex and sometimes contradictory roles of core TFs in both T cell function and dysfunction. Finally, we review strategies to target TFs using small molecule modulators, which represent a challenging but highly promising opportunity to tune the T cell response toward sustained immunity.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Trends Biochem Sci Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Trends Biochem Sci Ano de publicação: 2024 Tipo de documento: Article